---
title: Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
date: '2024-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39555820/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241118172045&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among patients with ischemic cardiomyopathy and ventricular
  tachycardia, an initial strategy of catheter ablation led to a lower risk of a composite
  primary end-point event than antiarrhythmic drug therapy. (Funded by the Canadian
  Institutes of Health Research and others; VANISH2 ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with ischemic cardiomyopathy and ventricular tachycardia, an initial strategy of catheter ablation led to a lower risk of a composite primary end-point event than antiarrhythmic drug therapy. (Funded by the Canadian Institutes of Health Research and others; VANISH2 ClinicalTrials.gov number, ...